Chemical exposure is one possible trigger, not the whole story
Instead, it stems from subcortical and autonomic mechanisms that hit adults aged 65 and older and patients with Type 2 diabetes particularly hard, highlighting an urgent need for proactive clinical supervision and medication de-escalation
When administered therapeutically, GLP-1 receptor agonists work through several mechanisms: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner [1] [4] Suppressing glucagon release from alpha cells, reducing hepatic glucose output Slowing gastric emptying , which helps moderate post-meal blood glucose rises Promoting satiety through central nervous system pathways, potentially supporting weight reduction Investigational transdermal GLP-1 delivery systems typically utilise specialised technologies such as microneedles or active delivery methods rather than conventional patches, as GLP-1 molecules are large peptides that do not easily penetrate the skin barrier
Cottage cheese is an additive play: it brings protein, creaminess, indulgence (and probiotics for Good Culture ) simultaneously
It activates monocarboxylic acid transporter 1 (MCT-1) and succinyl-coA transferase in the heart, enzymes involved in ketolysis [87]